Cancer vaccine - Xenova/Oxxon

Drug Profile

Cancer vaccine - Xenova/Oxxon

Alternative Names: DISC-GM-CSF

Latest Information Update: 08 Aug 2007

Price : $50

At a glance

  • Originator
  • Developer Xenova Group
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Malignant melanoma

Most Recent Events

  • 17 Jan 2005 DISC-GM-CSF has been licensed to Oxxon Therapeutics worldwide
  • 28 Jul 2004 DISC-GM-CSF is available for partnering (http://www.xenova.co.uk)
  • 28 Jun 2001 Cantab Pharmaceuticals has been acquired by Xenova Group
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top